A phase II, open-label, multinational, multi-centre, sequential group, dose-escalation study to assess the safety and antiviral activity of LB80380 for 24 weeks in patients with chronic hepatitis B who have developed lamivudine-resistant (YMDD mutant) HBV
Grant Data
Project Title
A phase II, open-label, multinational, multi-centre, sequential group, dose-escalation study to assess the safety and antiviral activity of LB80380 for 24 weeks in patients with chronic hepatitis B who have developed lamivudine-resistant (YMDD mutant) HBV
Principal Investigator
Emeritus Professor Lai, Ching Lung
(Principal Investigator (PI))
Co-Investigator(s)
Professor Yuen Richard Man Fung
(Co-Investigator)
Duration
33
Start Date
2004-05-20
Amount
678714
Conference Title
A phase II, open-label, multinational, multi-centre, sequential group, dose-escalation study to assess the safety and antiviral activity of LB80380 for 24 weeks in patients with chronic hepatitis B who have developed lamivudine-resistant (YMDD mutant) HBV
Presentation Title
Keywords
Chronic Hepatitis B
Discipline
Gastroenterology/Hepatobiliary
HKU Project Code
N/A
Grant Type
LG Life Sciences, Ltd. - General Award
Funding Year
2003
Status
Completed